Document is current

Article History

Received: 20 January 2026

Accepted: 24 June 2026

First Online: 1 July 2026

Declarations

:

: Clinical trial number: not applicable.

: MK is a co-founder of Twin Peaks, Forta and AptaDiR Therapeutics with stock options. He is a co-inventor of CpG-STAT3ASO strategy with pending patent application. STR is founder and chair of the scientific advisory board at SLAM bio and Noval Biotech. He is on the scientific advisory board of Cizzle. He is on the board of directors of Zylem. JK received a grant from Metavivor, and consulting fees from Johnson and Johnson, Boston Scientific, and Galvanize Therapeutics. CHC received support for attending meetings from Boston Scientific and Stryker. He is a co-investigator on studies funded by Instylla and CrannMed. FEB received research grants from City of Hope, Guerbet, Stephenson fund, COH-Caltech Biomedical Research Initiative (Merkin Institute), Society of Interventional Radiology, Society of Interventional Oncology, NIH/NCI, Department of Defense, Thompson family foundation, and Brockman Medical Research Foundation. He received research supplies (investigator-initiated) from Boston Scientific, and attended research consensus panels with the Society of Interventional Oncology. He is a co-founder of Claripacs, LLC, and an investor in Labdoor, Qventus, CloudMedx, Xgenomes, and Solugen. He has patent applications covering intratumoral drug delivery devices, immunoembolization, Y90 dosimetry, endoluminal ablation, CT metal artifact reduction, and other inventions.